Report of Foreign Issuer (6-k)
June 23 2015 - 5:01PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
OF THE SECURITIES EXCHANGE ACT OF 1934
For the month of June 2015
Commission File Number 001-36866
SUMMIT
THERAPEUTICS PLC
(Translation of registrants name into English)
85b Park Drive
Milton
Park, Abingdon
Oxfordshire OX14 4RY
United Kingdom
(Address
of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
FORM
20-F x FORM 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T
Rule 101(b)(7): ¨
Indicate by check mark whether the registrant by furnishing the information
contained in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934:
YES ¨ NO
x
If Yes is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b):
On June 22, 2015, Summit Therapeutics plc (the Company) announced details of purchases of the
Companys American Depositary Shares (ADSs) by Mr David Wurzer, a Non-Executive Director of the Company. The press release is attached hereto as Exhibit 99.1 and incorporated by reference herein.
The information contained in Exhibits 99.1 shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as
amended (the Exchange Act), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
|
|
|
|
|
SUMMIT THERAPEUTICS PLC |
|
|
By: |
|
/s/ Erik Ostrowski |
|
|
Erik Ostrowski |
|
|
Chief Financial Officer |
Date: June 23, 2015
EXHIBIT INDEX
|
|
|
Exhibit Number |
|
Description |
|
|
99.1 |
|
Press Release dated June 22, 2015 regarding ADS purchases |
Exhibit 99.1
Summit Therapeutics plc
(Summit or the Company)
DIRECTOR SHARE DEALING
Oxford, UK, 22 June
2015 Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and C. difficile infection, announces that Company has been notified that Mr
David Wurzer, Non-Executive Director of the Company, has on 18 June 2015 bought 1,500 American Depositary Shares (ADSs) of Summit at a price of $11.65 per ADS.
Following this notification Mr Wurzers beneficial interest in Summit Shares is 1,500 ADSs (equivalent to 7,500 ordinary shares on 1p nominal value),
representing approximately 0.01% of the Companys current issued share capital.
The ADSs were acquired on the NASDAQ Global Market. This
notification relates to disclosures made in accordance with Rule 17 Schedule 5 of the AIM Rules.
- END -
For more information, please contact:
|
|
|
|
|
Summit Therapeutics |
|
|
|
|
Richard Pye (UK office) |
|
Tel: |
|
+44 (0)1235 443 951 |
Erik Ostrowski (US office) |
|
|
|
+1 617 294 6607 |
|
|
|
Cairn Financial Advisers LLP |
|
|
|
|
(Nominated Adviser) |
|
|
|
|
Liam Murray / Tony Rawlinson |
|
Tel: |
|
+44 (0)20 7148 7900 |
Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart
From Jul 2023 to Jul 2024